The FDA has granted Priority Review to durvalumab for the treatment of resectable, early-stage and locally advanced (Stage II-IVA) gastric and gastroesophageal junction cancers.

The FDA recommendation follows a detailed scientific review and is part of broader efforts to address concerns about the rise of 7-OH opioid products. Currently, 7-OH has no FDA-approved drug uses and ...

There have been 402 “attacks on science” in the first 6 months of President Donald Trump’s second term, a new report suggests.

A federal judge blocked a law that directed the federal government to stop Medicaid payments to many abortion providers.